Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nihon Kohden Corporation (6849.T)
Tokyo, JP
Nihon Kohden Corporation, founded in 1951 and headquartered in Tokyo, Japan, is a global leader in healthcare technology. The company’s core operations encompass the research, development, manufacturing, sales, repair, and maintenance of advanced medical electronic equipment, serving markets across Japan, the Americas, Europe, Asia, and other international regions. Its extensive product range features sophisticated physiological measurement instruments, including electroencephalographs (EEGs), electrocardiographs (ECGs), evoked potential and electromyogram (EMG) systems, and polygraphs for cardiac catheterization laboratories. These offerings are integrated with diagnostic information systems and supported by essential consumables like recording papers, electrodes, and catheters, along with comprehensive maintenance services. Nihon Kohden also delivers cutting-edge patient monitoring solutions, such as central, bedside, and wireless monitors, alongside remote access software. These are seamlessly linked with clinical information systems and provided with associated disposables, including various electrodes and sensors. The company's therapeutic device portfolio includes critical equipment like defibrillators (including automated external defibrillators or AEDs), ventilators, pacemakers, anesthesia machines, and cochlear implants. Necessary consumables, such as AED pads and batteries, and related services are also supplied for these products. Furthermore, Nihon Kohden offers other specialized medical apparatus, such as hematology and clinical chemistry analyzers, ultrasound diagnostic equipment, and tools for research purposes. These are accompanied by consumables like test reagents, installation services, and ongoing maintenance. Beyond its primary focus on medical devices, the corporation also participates in insurance brokerage and technology licensing.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.27% | +3.46% | -3.67% | -12.31% | -6.12% | -12.57% | -18.55% | -21.72% | -5.49% | -6.68% | +1,569.30% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 2 | 0 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+4.3% Q1'26: +6.2% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+5.2% Q1'26: +36.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+8.2% ★ Q1'26: +10.6% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+8.0% ★ Q1'26: +11.2% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+8.7% ★ Q1'26: +16.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-2.1% ★ Q1'26: -0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×1.02× ★ Q1'26: 0.66× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 8 Rev. Ana. 8 EPS Ana. |
Mar 2027 4 Rev. Ana. 5 EPS Ana. |
Mar 2028 8 Rev. Ana. 8 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
Mar 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
160.80B
est: 160.30B (+0.3%)
|
165.52B
est: 166.00B (-0.3%)
|
166.29B
est: 166.61B (-0.2%)
|
174.25B
est: 174.21B (+0.0%)
|
178.80B
est: 179.50B (-0.4%)
|
185.01B
est: 185.44B (-0.2%)
|
199.73B
est: 193.70B (+3.1%)
|
205.13B
est: 204.99B (+0.1%)
|
206.60B
est: 207.48B (-0.4%)
|
221.99B
est: 219.49B (+1.1%)
|
225.42B
est: 226.74B (-0.6%)
|
233.44B
230.60B – 235.27B
+3.0% YoY
|
230.01B
224.03B – 234.01B
-1.5% YoY
|
233.15B
225.00B – 256.12B
+1.4% YoY
|
238.59B
231.31B – 252.44B
+2.3% YoY
|
248.12B
240.55B – 262.52B
+4.0% YoY
|
257.55B
249.70B – 272.50B
+3.8% YoY
|
| EBITDA |
19.53B
est: 23.89B (-18.3%)
|
20.06B
est: 24.74B (-18.9%)
|
17.15B
est: 24.83B (-30.9%)
|
18.01B
est: 25.97B (-30.7%)
|
18.74B
est: 26.75B (-30.0%)
|
19.25B
est: 27.64B (-30.4%)
|
31.64B
est: 28.87B (+9.6%)
|
34.48B
est: 30.55B (+12.9%)
|
24.91B
est: 30.92B (-19.4%)
|
23.45B
est: 26.75B (-12.4%)
|
24.90B
est: 27.64B (-9.9%)
|
28.45B
28.11B – 28.68B
+3.0% YoY
|
28.03B
27.31B – 28.52B
-1.5% YoY
|
28.42B
27.42B – 31.22B
+1.4% YoY
|
29.08B
28.19B – 30.77B
+2.3% YoY
|
30.24B
29.32B – 32.00B
+4.0% YoY
|
31.39B
30.43B – 33.21B
+3.8% YoY
|
| EBIT |
15.92B
est: 20.88B (-23.7%)
|
16.44B
est: 21.62B (-24.0%)
|
13.59B
est: 21.70B (-37.4%)
|
14.52B
est: 22.69B (-36.0%)
|
15.05B
est: 23.38B (-35.6%)
|
15.50B
est: 24.15B (-35.8%)
|
27.10B
est: 25.23B (+7.4%)
|
30.99B
est: 26.70B (+16.1%)
|
21.12B
est: 27.02B (-21.8%)
|
19.59B
est: 22.54B (-13.1%)
|
20.71B
est: 23.28B (-11.0%)
|
23.97B
23.68B – 24.16B
+3.0% YoY
|
23.62B
23.00B – 24.03B
-1.5% YoY
|
23.94B
23.10B – 26.30B
+1.4% YoY
|
24.50B
23.75B – 25.92B
+2.3% YoY
|
25.48B
24.70B – 26.95B
+4.0% YoY
|
26.44B
25.64B – 27.98B
+3.8% YoY
|
| Net Income |
11.14B
est: 11.71B (-4.9%)
|
10.52B
est: 10.05B (+4.7%)
|
9.15B
est: 9.62B (-4.9%)
|
9.15B
est: 9.87B (-7.2%)
|
11.19B
est: 10.64B (+5.2%)
|
9.85B
est: 10.16B (-3.0%)
|
18.24B
est: 13.22B (+38.0%)
|
23.44B
est: 20.79B (+12.7%)
|
17.11B
est: 14.64B (+16.9%)
|
17.03B
est: 14.01B (+21.6%)
|
14.10B
est: 13.47B (+4.7%)
|
12.68B
11.97B – 13.92B
-5.8% YoY
|
15.86B
15.35B – 16.37B
+25.0% YoY
|
16.52B
14.92B – 18.12B
+4.2% YoY
|
17.07B
16.06B – 19.14B
+3.3% YoY
|
18.89B
18.15B – 20.32B
+10.7% YoY
|
18.21B
17.49B – 19.59B
-3.6% YoY
|
| SGA |
53.58B
est: 57.60B (-7.0%)
|
56.03B
est: 59.65B (-6.1%)
|
56.84B
est: 59.86B (-5.1%)
|
58.59B
est: 62.60B (-6.4%)
|
61.37B
est: 64.50B (-4.8%)
|
64.72B
est: 66.63B (-2.9%)
|
66.60B
est: 69.60B (-4.3%)
|
70.02B
est: 73.65B (-4.9%)
|
75.94B
est: 74.55B (+1.9%)
|
81.98B
est: 81.36B (+0.8%)
|
86.76B
est: 84.05B (+3.2%)
|
86.53B
85.48B – 87.21B
+3.0% YoY
|
85.26B
83.04B – 86.74B
-1.5% YoY
|
86.43B
83.40B – 94.94B
+1.4% YoY
|
88.44B
85.74B – 93.58B
+2.3% YoY
|
91.97B
89.17B – 97.31B
+4.0% YoY
|
95.47B
92.56B – 101.01B
+3.8% YoY
|
| EPS |
63.41
est: 70.51 (-10.1%)
|
60.06
est: 60.48 (-0.7%)
|
53.41
est: 57.89 (-7.7%)
|
53.46
est: 59.39 (-10.0%)
|
65.71
est: 64.04 (+2.6%)
|
57.86
est: 61.14 (-5.4%)
|
107.10
est: 79.60 (+34.5%)
|
138.25
est: 125.15 (+10.5%)
|
101.64
est: 88.00 (+15.5%)
|
101.22
est: 83.32 (+21.5%)
|
84.87
est: 84.11 (+0.9%)
|
77.82
73.60 – 85.60
-7.5% YoY
|
96.67
94.40 – 100.68
+24.2% YoY
|
101.98
91.73 – 111.44
+5.5% YoY
|
108.00
98.77 – 117.68
+5.9% YoY
|
116.20
111.59 – 124.97
+7.6% YoY
|
112.00
107.56 – 120.45
-3.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | B+ | 3/5 | 4/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Eiichi Tanaka | Executive Operating Officer, Chief Operating Officer & Corporate Director | — | male |
| Eri Watanabe | Operating Officer, Deputy GM of Global Corporation Administration Operations & GM of Finance Department | — | — |
| Hirohiko Ikeya | Operating Officer, Chief Technology Officer & GM of Technology Development Operations | — | — |
| Hirokazu Ogino | Chairman, President & Chief Executive Officer | — | male |
| Kaoru Imajo | Operating Officer, CIO, GM of Neurology Bus. Divi. & CEO of Ad-Tech Medical Instrument Co. | — | — |
| Kazuhiro Kato | Sr. Op. Off., CAO & GM of Corp. Adm. Ope. and Chief Com. Off. & Corporate Director | — | male |
| Kazuomi Shimoda | Operating Officer, Chief Business Development Officer (CBDO) & GM of Import Business Operations | — | — |
| Keichiro Yoshizawa | Executive Officer & Head of North American Business Headquarters | — | — |
| Kenji Furukawa | Senior Op. Officer, Chief Human Capital Officer, GM of HR Development Operations & GM of HR Dept | — | — |
| Naoto Nishii | Executive Officer & Head of Business Strategy Headquarters | — | — |
| Seiji Miyazaki | Executive Officer & Head of Overseas Business Headquarters | — | — |
| Toshihiko Hiraoka | Op. Officer, Chief Regional Officer - Japan | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 6849.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
